Arecor Therapeutics PLC Arecor Granted Key Canadian Patent (0205S)
11 November 2021 - 6:00PM
UK Regulatory
TIDMAREC
RNS Number : 0205S
Arecor Therapeutics PLC
11 November 2021
Arecor Therapeutics plc
("Arecor" or the "Group")
ARECOR GRANTED KEY CANADIAN PATENT FOR PROPRIETARY TECHNOLOGY
ENABLING HIGHLY CONCENTRATED BIOTHERAPEUTICS
Cambridge, UK, 11 November 2021. Arecor Therapeutics plc (AIM:
AREC), the biopharmaceutical group advancing today's therapies to
enable healthier lives, continues to build a strong patent
portfolio protecting its proprietary Arestat(TM) technology. Arecor
is pleased to announce that the Canadian Intellectual Property
Office has granted a key patent, CA2861402, with claims protecting
a specific part of the technology used in the development of
stable, low-viscosity formulations of highly concentrated protein
therapeutics, including monoclonal antibodies, fusion proteins and
more complex protein constructs.
Dr Jan Jezek, Chief Scientific Officer at Arecor, commented :
"The recently granted Canadian patent is an important milestone in
our rapidly growing patent portfolio. We have been very successful
in patenting unique combinations of excipients that improve
considerably critical quality attributes of protein and
peptide-based therapeutics, enabling their convenient delivery.
This new patent relates specifically to concentrated protein
formulations, which is one of the most challenging areas of the
biopharmaceutical drug delivery. It strengthens our IP portfolio
and our position as a world leader in the formulation of superior
biotherapeutics and vaccines."
The Group's Arestat(TM) technology enables superior product
profiles across a broad range of therapies, including various types
of biopharmaceuticals, specialty hospital products as well as
vaccine compositions with improved stability. Arecor partners with
leading pharmaceutical and biotechnology companies to deliver
enhanced formulations of their therapeutic products under a
technology licensing model, as well as developing an internal
portfolio of proprietary products in diabetes and other
indications.
A combination of high therapeutic dose and the highly desirable
low injection volume often leads to a need for very highly
concentrated formulations of protein therapeutics. Achieving such
concentrated formulations can be exceptionally challenging. The
granted Canadian patent provides Arecor's proprietary technology
with broad protection in the formulation of highly concentrated
compositions of therapeutic proteins, enabling convenient
subcutaneous delivery of high value products to a higher
specification compared with other approaches. It adds to patents
already issued from the same patent family by Patent Offices in
Europe, the US and India.
Arecor has invested in building a strong patent portfolio to
protect the Arestat(TM) technology platform. The Group's
intellectual property portfolio currently comprises 33 patent
families, including >50 granted patents in Europe in the US and
in other key territories.
-ENDS-
For more information, please contact:
Arecor Therapeutics plc www.arecor.com
Dr Sarah Howell, Chief Executive Officer Tel: +44 (0) 1223 426060
Email: info@arecor.com
Susan Lowther, Chief Financial Officer Tel: +44 (0) 1223 426060
Email: info@arecor.com
Mo Noonan, Communications Tel: +44 (0) 7876 444977
Email: mo.noonan@arecor.com
Panmure Gordon (UK) Limited (NOMAD Tel: +44 (0) 20 7886 2500
and Broker)
Freddy Crossley, Emma Earl (Corporate
Finance)
Rupert Dearden (Corporate Broking)
Consilium Strategic Communications
Chris Gardner, David Daley, Angela Tel: +44 (0) 20 3709 5700
Gray Email: arecor@consilium-comms.com
Notes to Editors
About Arecor
Arecor Therapeutics plc is a globally focused biopharmaceutical
company transforming patient care by bringing innovative medicines
to market through the enhancement of existing therapeutic products.
By applying our innovative proprietary formulation technology
platform, Arestat(TM) , we are developing an internal portfolio of
proprietary products in diabetes and other indications, as well as
working with leading pharmaceutical and biotechnology companies to
deliver enhanced formulations of their therapeutic products. The
Arestat (TM) platform is supported by an extensive patent portfolio
.
For further details please see our website, www.arecor.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCFBLLFFFLLFBD
(END) Dow Jones Newswires
November 11, 2021 02:00 ET (07:00 GMT)
Arecor Therapeutics (LSE:AREC)
Historical Stock Chart
From Apr 2024 to May 2024
Arecor Therapeutics (LSE:AREC)
Historical Stock Chart
From May 2023 to May 2024